<DOC>
	<DOC>NCT00107952</DOC>
	<brief_summary>Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.</brief_summary>
	<brief_title>Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration. Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Grampositive pneumonia immediately prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Nosocomial pneumonia</keyword>
	<keyword>MRSA</keyword>
</DOC>